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PLINICAL RESEARCH Interventional Cardiology
Randomized Comparison
f Sirolimus-Eluting Stent With Balloon
ngioplasty in Patients With In-Stent Restenosis
esults of the Restenosis Intrastent: Balloon Angioplasty
ersus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial
ernando Alfonso, MD,* Maria-José Pérez-Vizcayno, MD,* Rosana Hernandez, MD,*
rmando Bethencourt, MD,† Vicens Martí, MD,‡ Jose R. López-Mínguez, MD,§ Juan Angel, MD,
amón Mantilla, MD,¶ Cesar Morís, MD,# Angel Cequier, MD,** Manel Sabaté, MD,*
avier Escaned, MD,* Raúl Moreno, MD,* Camino Bañuelos, MD,* Alfonso Suárez, MD,*
arlos Macaya, MD,* for the RIBS-II Investigators
adrid, Palma de Mallorca, Barcelona, Badajoz, Vigo, and Oviedo, Spain
OBJECTIVES We sought to assess the effectiveness of sirolimus-eluting stents (SES) in patients with
in-stent restenosis (ISR).
BACKGROUND Treatment of patients with ISR remains a challenge.
METHODS The Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting
(RIBS-II) study is a multicenter randomized trial conducted in 150 patients with ISR (76
allocated to SES and 74 to balloon angioplasty [BA]). The primary end point was recurrent
restenosis rate at nine months. Secondary end points included prespecified subgroup analysis,
lumen volume on intravascular ultrasound (IVUS), and a composite of major clinical events
at one year.
RESULTS Angiographic success was obtained in all patients. At 9-month angiographic follow-up (96%
of eligible patients) minimal lumen diameter was larger (2.52 mm [interquartile range (IQR)
2.09 to 2.81] vs. 1.54 mm [IQR 0.91 to 2.05]; p  0.001) and recurrent restenosis rate was
lower (11% vs. 39%; p  0.001) in the SES group. Prespecified subgroup analyses were
consistent with the main outcome measure. Lumen volume on IVUS at 9 months was also
larger (279 mm3 [IQR 227 to 300] vs. 197 mm3 [IQR 177 to 230]; p  0.001) in the SES
group. At one-year clinical follow-up (100% of patients), the event-free survival (freedom
from death, myocardial infarction, and target vessel revascularization) was significantly
improved in the SES group (88% vs. 69%; p  0.004) as the result of a lower requirement
for target vessel revascularization (11% vs. 30%; p  0.003).
CONCLUSIONS In patients with ISR, the use of SES provides superior long-term clinical, angiographic, and
IVUS outcome than BA treatment. (J Am Coll Cardiol 2006;47:2152–60) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.078American College of Cardiology Foundation
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soronary stents currently constitute the default strategy
uring percutaneous coronary interventions (PCI) (1–3).
owever, prevention and treatment of in-stent restenosis
See page 2161
ISR) remain among the most important challenges of
nterventional cardiology (1–3). Different therapeutic strat-
gies have been used in patients with ISR, but all of them
From the *Clinico San Carlos University Hospital, Madrid, Spain; †Son Dureta
niversity Hospital, Palma de Mallorca, Spain; ‡San Pablo University Hospital,
arcelona, Spain; §Infanta Cristina University Hospital, Badajoz, Spain; Valle de
ebrón University Hospital, Barcelona, Spain; ¶Meixoeiro University Hospital,
igo, Spain; #Central Asturias University Hospital, Oviedo, Spain; and **Bellvitge
niversity Hospital, Barcelona, Spain. An unrestricted grant was obtained from
ordis, Spain.p
Manuscript received August 21, 2005; revised manuscript received October 14,
005, accepted October 25, 2005.re shadowed by a high recurrence risk, especially in patients
resenting diffuse ISR (4–8). As compared with balloon
ngioplasty, still the most frequently used therapy for ISR,
epeated bare-metal stenting is able to guarantee optimal
mmediate results but exacerbates neointimal proliferation
nd, eventually, fails to significantly improve long-term
linical and angiographic outcome (9,10). In this context,
he dramatic capacity of drug-eluting stents to inhibit
eointimal proliferation has generated renewed expectations
2). Preliminary observational studies have demonstrated
ncouraging results with the use of these new stents in
atients with ISR (11–14). Moreover, recent studies suggest
hat drug-eluting stents might even be superior to brachy-
herapy which, up to now, constitutes the only proven
ffective therapy in this challenging scenario (15–17).
The aim of this randomized study was to compare
irolimus-eluting stents with conventional balloon angio-
lasty in patients with ISR.
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atient selection and study design. The Restenosis In-
rastent: Balloon Angioplasty Versus Elective Sirolimus-
luting Stenting (RIBS-II) study was designed as a pro-
pective, multicenter, randomized clinical trial to compare
hese two therapeutic strategies in patients with ISR (Ap-
endix). Inclusion and exclusion criteria were similar to
hose in the RIBS-I trial (a previous randomized study
omparing balloon angioplasty with bare-metal stenting for
SR) (10).
Briefly, patients with a first ISR (50% diameter steno-
is) after bare-metal stenting were eligible if they presented
ith a clinical indication for repeat PCI (angina or docu-
ented ischemia) and had lesions amenable for both ther-
peutic strategies. Patients with ISR on small vessels (2.5
m in diameter on visual assessment), occluded arteries, or
ery diffuse ISR (32 mm in length) were excluded.
atients with early (4 weeks) ISR, those presenting with
n acute myocardial infarction, and patients with a prior
rachytherapy procedure were also excluded. Contraindica-
ions to aspirin or clopidogrel, and severe concomitant
iseases interfering with follow-up, were additional pre-
pecified exclusion criteria.
Randomization was centralized by telephone at the co-
rdinating center (Clínico San Carlos University Hospital,
adrid) using a computer-generated code and was stratified
ccording to lesion length. Eight university hospitals from
pain participated in the trial. All patients gave written
nformed consent. The study was performed according to
he provisions of the Declaration of Helsinki regarding
nvestigations with human subjects (18), was designed and
onducted according to the CONSORT recommendations
19), and was approved by the corresponding institutional
thics committees. The trial was an investigators-driven
nitiative.
oronary interventions. All patients were pretreated with
spirin. In elective cases clopidogrel was administered before
he procedure. Patients undergoing “ad-hoc” procedures re-
eived a loading dose of 300 or 600 mg clopidogrel immedi-
tely after the procedure. During interventions heparin was
iven to maintain an activated clotting time 250 s.
In the balloon arm, balloon size was selected to achieve a
Abbreviations and Acronyms
BA  balloon angioplasty
IQR  interquartile range
ISR  in-stent restenosis
IVUS  intravascular ultrasound
PCI  percutaneous coronary interventions
RIBS-II  Restenosis Intrastent: Balloon Angioplasty
Versus Elective Sirolimus-Eluting Stenting
study
SES  sirolimus-eluting stentsnal balloon-to-artery ratio of 1.1:1. In the sirolimus- nluting stent arm the protocol mandated a careful lesion
redilation. In particular, the use of undersized (1 mm
elow reference vessel diameter) and short balloons was
trongly recommended. Likewise, the protocol emphasized
he importance of full lesion coverage (including the predi-
ated segment) with the sirolimus stent. If 1 stent was
equired a 2- to 3-mm overlap was advocated. Sirolimus-
luting stents (Cypher, Cordis Corp., Johnson & Johnson
o., Miami Lakes, Florida) were available in diameters of
.5, 2.75, 3.0, and 3.5 mm and in lengths of 8, 13, 18, 23,
nd 33 mm. Relatively high pressures (12 atm) were
ecommended in both arms. In the balloon arm, prolonged
alloon inflations had to be performed before crossover to
are-metal stenting (residual stenosis 50% or major/
schemia-inducing dissections) (10).
Serum creatine kinase levels (with MB values if abnor-
al) and 12-lead electrocardiograms were obtained before,
mmediately after the procedure and then serially for 24 h.
fter the procedure all patients received aspirin indefinitely
100 to 300 mg daily) and clopidogrel (75 mg/day) for nine
onths.
ollow-up and definitions. Patients were followed up at
ne month, nine months, and one year. Angiographic
ollow-up was obtained routinely at nine months or earlier
f clinically indicated. If restenosis was not demonstrated in
n angiogram performed 3 months after the index proce-
ure a second angiography was indicated at 9 months. An
xercise test was recommended before the scheduled an-
iography. Case-report forms were completed at each site,
ubmitted to the coordinating center, and entered into a
edicated database. Consistency checks were systematically
erformed, and, whenever needed, queries were sent back to
he sites. All major events were verified against source
ocumentation. Clinical events (death, myocardial infarc-
ion, target vessel revascularization) were adjudicated by an
ndependent Clinical Events Committee blinded to the
ssigned treatment. Death was considered to be cardiac
nless a noncardiac cause could be demonstrated. Myocar-
ial infarction required two of the following: 1) prolonged
30 min) chest pain; 2) creatine kinase rise above twice the
pper normal value (with an abnormal MB fraction); and 3)
ppearance of new pathologic Q waves. The protocol
andated that repeated PCI at follow-up could only be
erformed in the presence of symptoms or ischemia.
ngiographic analysis. Coronary angiograms were care-
ully analyzed at the angiographic core laboratory, following
tandard morphologic criteria (9,10), by personnel blinded
o treatment allocation. The Mehran classification was also
sed to assess the pattern of ISR (4).
Quantitative coronary angiographic analysis was per-
ormed with an automatic edge-detection system (CMS 4.0,
edis, Leiden, the Netherlands). Preselected matched an-
iographic views (after intracoronray nitroglycerin) were
btained and analyzed before and after intervention and at
ine-month follow-up. The angiographic analysis included
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egion, and the adjacent vessel (5 mm) on each side (10). A
econd analysis, confined to the lesion site, was also made.
estenosis was defined as 50% diameter stenosis at
ollow-up.
ntravascular ultrasound (IVUS) analysis. As a substudy,
VUS imaging was performed before intervention, after the
rocedure, and at follow-up following administration of
ntracoronary nitroglycerin. A mechanical system, with a
0-MHz transducer was used (Boston Scientific, Sunnyvale,
alifornia). The imaging sequence started 1 cm distal to the
istal edge of the stent and ended at the aortocoronary
unction. The transducer was withdrawn at a constant speed
f 0.5 mm/s using a motorized pullback device. Studies were
ecorded on a 0.5-inch s-VHS tape. Subsequently digitiza-
ion was performed at a workstation designed for three-
imensional image reconstruction (Echoscan, Tomtec, Ger-
any). A previously validated semiautomatic contour-
etection program was used at the core-lab for volumetric
nalysis (9). Lumen volume was measured in stent and in
egment (stent  5-mm edges). Neointimal volume was
nalyzed within the stent. In the balloon arm neointimal
roliferation was defined as neointimal volume at follow-up
inus residual neointimal volume after the intervention.
tudy end points. The primary end point was the recurrent
estenosis rate at follow-up (in-segment analysis). Second-
ry angiographic end points were minimal lumen diameter
nd late loss at follow-up. Secondary IVUS end points
ncluded lumen volume and neointimal proliferation volume
t follow-up. Finally, the rate of target vessel revasculariza-
ion and the event-free survival at one year were also
econdary clinical end points.
tatistical analysis. SAMPLE SIZE CALCULATION. Follow-
ng the results of the RIBS-I study, we assumed a restenosis
ate of 40% in the balloon arm (10). A restenosis rate of 15%
as estimated for the sirolimus-eluting stent arm (11,12).
herefore, selecting a power of 90% and an alpha value of
.05, and considering that it would be necessary to com-
ensate for 10% loss in late angiography, a total number of
50 patients (75 in each arm) was eventually calculated.
Data are presented as values and percentages or mean 
D. Median and interquartile range (IQR) were used when
ata was not normally distributed (Kolmogorov-Smirnov
est). Categoric variables were compared with the chi-
quared test or Fisher exact test (expected n of 5). The
tudent t test, the median test, or the sign test (paired
ample) were used for the comparison of continuous vari-
bles. Event-free survival was estimated by Kaplan-Meier
nalysis and compared with the log rank test. Relative risks
nd 95% confidence intervals (CI) were calculated. A
respecified analysis of 10 relevant baseline variables (similar
o RIBS-I) (10) was also performed. All analyses were
erformed according to the intention-to-treat principle
SPSS package, version 12.0, SPSS Inc., Chicago, Illinois).p value of 0.05 was considered statistically significant. sESULTS
rom February 2003 to April 2004, 150 patients with ISR
ere enrolled and randomly assigned to sirolimus stenting
76 patients) or balloon angioplasty (74 patients) (Fig. 1).
aseline clinical and angiographic characteristics were sim-
lar in both groups (Table 1). Procedural characteristics were
lso similar in both groups although longer balloon inflation
imes were used in the balloon group (Table 1). Final
ressures were higher than those used in the RIBS-I study
10). Angiographic success was obtained in all patients
100%). The sirolimus stent was successfully implanted in
ll patients (in 69 after predilation and as direct stenting in
). Twelve patients required 1 sirolimus stent. One
atient in the sirolimus stent group died 17 days after the
rocedure from sepsis (20), and no other major events
ccurred during hospitalization.
Results of the quantitative angiography analysis are
hown in Table 2. Baseline findings were similar in both
roups, although a diffuse pattern of ISR tended to be more
requent in the sirolimus stent group. After the procedure,
owever, better angiographic results were obtained in the
irolimus stent group (including minimal lumen diameter and
diameter stenosis). Late angiographic follow-up (260  48
ays, median 274 days) was obtained in 141 patients (96% of
hose eligible). Late angiographic results were significantly
etter in the sirolimus-eluting stent group (Table 2). The
ecurrent restenosis rate (primary study end point) was 11%
n the sirolimus stent group and 39% in the balloon group
p  0.001). In clinical terms, four patients with ISR need
o be treated with sirolimus stents to prevent one episode of
ecurrent ISR. The Mehran classification (I, II, and III) was
nable to predict late loss in the sirolimus stent group (0.02
0.15 to 0.28] mm, 0.16 [0.13 to 0.44] mm, and 0.13
0.11 to 0.95] mm, respectively; p  0.44), whereas it
igure 1. Flow chart of patients included in the trial and patients with final
ngiographic follow-up. BA  balloon angioplasty; FU  follow-up; ISR 
n-stent restenosis; Pts patients; QCA quantitative coronary angiography;
x  randomization; SES  sirolimus-eluting stents.ignificantly influenced late loss in the balloon group (0.50
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o 1.24] mm, respectively; p  0.03).
In the sirolimus-eluting stent group, patients with recur-
ent ISR had similar baseline clinical, angiographic, and
rocedural characteristics as patients without recurrent ISR.
ecurrence rate was similar in patients treated with high
16 atm) and lower pressures. However, patients with
ecurrences tended to have longer lesions (24  14 mm vs.
6  8 mm; p  0.14) and were treated with longer
irolimus stents (29  11 mm vs. 22  7 mm; p  0.05)
ompared with patients without recurrences. Recurrent ISR
fter sirolimus stenting tended to be relatively focal (11  5
m), with a significant reduction in length from the index
rocedure (reduction of 13 13 mm; p 0.05 vs. baseline).
igure 2 depicts cumulative frequency distribution curves of
inimal lumen diameter at all time points. Figure 3 displays
he subgroup analyses.
Intravascular ultrasound studies were obtained in 114
atients (76%). However, complete, serial studies of ade-
uate quality for quantitative analysis were available in 82
atients (42 sirolimus stent and 40 balloon group). Baseline
haracteristics of these patients were similar to those found
n the complete population. Ultrasound findings preinter-
ention were similar in both groups. After the procedure,
owever, a larger lumen volume was obtained in the stent
Table 1. Baseline Clinical, Angiographic, and
Characteristic SES Group
Age, yrs 64 
Female gender, n (%) 18 (24
Risk factors, n (%)
Diabetes mellitus 29 (38
Hyperlipidemia 43 (57
Hypertension 46 (61
Ever smoked 44 (58
Clinical features, n (%)
Unstable angina 31 (41
Stable angina 32 (42
Silent ischemia 13 (17
Previous myocardial infarction 44 (58
Previous bypass surgery 5 (7)
Time to restenosis, days (range) 194 (15
Target artery, n (%)
Left anterior descending 41 (54
Left circumflex 11 (14
Right coronary 24 (32
Saphenous vein graft 0 (0)
B2-C lesion, n (%) 62 (81
Mehran I, II, III,* n (%) 15 (20), 51 (
Ejection fraction, % 65 
Procedural characteristics
Length of initial stent (mm) 20 
Maximal pressure (atm) 15.8 
Total inflation time (s) 90 
Balloon/artery ratio 1.17 
Cross-over 0 (0)
Angiographic success 76 (10
*Mehran IV was not included. †Fisher test. ‡Median test.
BA  balloon angioplasty; SES  sirolimus-eluting stenroup. At late follow-up, lumen volume (both in-segment ind in-stent analyses) was significantly larger in the
irolimus-eluting stent group (Fig. 4). The volume of
eointimal proliferation was also significantly reduced in the
irolimus stent group (Fig. 4). At late follow-up, only 4%
IQR 3% to 7%) of the total sirolimus stent volume was
ccupied by neointima.
A complete one-year clinical follow-up was obtained in
ll 150 patients (100%). Table 3 summarizes all adverse
linical events documented during this time. Two patients
uffered an abrupt vessel closure and developed a Q-wave
yocardial infarction (one patient in each arm); hyperho-
ocysteinemia was found in an 80-year-old patient in the
irolimus stent arm in whom doubts emerged concerning
he correct intake of the dual antiplatelet regimen.
Overall clinical events at nine-month and one-year
ollow-up were significantly reduced in the sirolimus stent
roup. This was largely due to a lower requirement for
arget vessel revascularization which, in some patients, was
erformed after nine months once ischemia was demon-
trated (Table 3).
ISCUSSION
his randomized study demonstrates the superiority of
irolimus-eluting stents, compared with balloon angioplasty,
dural Characteristics
76) BA Group (n  74) p Value
64  10 0.76
19 (26) 0.77
23 (31) 0.36
49 (66) 0.23
36 (49) 0.14
44 (59) 0.85
37 (50) 0.26
27 (37) 0.48
10 (14) 0.54
38 (51) 0.42
3 (4) 0.72†
) 209 (174–323) 0.63‡
0.72
38 (52)
12 (16)
23 (31)
1 (1)
58 (78) 0.62
0 (13) 25 (34), 41 (55), 8 (11) 0.15
66  10 0.38
21  9 0.55
15.5  3.1 0.64
132  109 0.005
1.14  0.1 0.37
6 (8) 0.01†
74 (100) 1Proce
(n 
11
)
)
)
)
)
)
)
)
)
8–296
)
)
)
)
67), 1
11
8
2.9
63
0.1
0)n patients with ISR. Patients treated with sirolimus-eluting
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Sirolimus Stents for In-Stent Restenosis June 6, 2006:2152–60tents had a dramatic improvement in all angiographic
arameters at follow-up, including recurrent restenosis rate,
he primary end point of the study. This was the result not
nly of a better initial angiographic result, but also, more
mportantly, of a marked reduction in the angiographic late
oss. Subgroup analyses were consistent with the main
utcome measure. In addition, the use of sirolimus stents,
ssociated with prolonged dual antiplatelet therapy, proved
igure 2. Cumulative frequency distribution curves of minimal lumen
iameter (MLD) (in-segment analysis) before the procedure (PRE), after
Table 2. Initial and Follow-Up Angiographic R
Variable SE
Before the procedure* (n
Reference vessel diameter (mm) 2.6
Minimal lumen diameter (mm) 0.7
Stenosis (% of lumen diameter) 7
Lesion length (mm) 16
Diffuse lesions (10 mm), n (%) 61 (8
After the procedure* (n
Reference vessel diameter (mm) 2.9
Minimal lumen diameter (mm) 2.6
Stenosis (% of lumen diameter)
Acute gain (mm) 1.9
At follow-up (in-segment analysis)† (n
Reference vessel diameter (mm) 2.87 (2
Minimal lumen diameter (mm) 2.52 (2
Stenosis (% of lumen diameter) 8 (4
Restenosis, n (%) 8 (1
Late loss (mm) 0.13 (
Loss index 0.06 (
Net gain (mm) 1.81 (1
At follow-up (in-lesion analysis)† (n
Reference vessel diameter (mm) 2.85 (2
Minimal lumen diameter (mm) 2.56 (2
Stenosis (% of lumen diameter) 8 (4
Restenosis, n (%) 5 (7
Late loss (mm) 0.11 (
Loss index 0.06 (
Net gain (mm) 1.84 (1
*Values before and after the procedure followed a gaussian
normally distributed (median, interquartile range), were com
Abbreviations as in Table 1.I
ntervention (POST), and at follow-up (FU), in patients treated with
alloon angioplasty (BA) and sirolimus-eluting stenting (SES).o be safe in this challenging setting with an incidence of
brupt vessel closure similar to that found in the balloon
roup. Moreover, our IVUS substudy provided further
echanistic insights and demonstrated the ability of
irolimus-eluting stents to virtually abolish recurrent neoin-
imal proliferation. Finally, these excellent late angiographic
nd ultrasound findings translated into an improved clinical
utcome, mainly as the result of a significant reduction in
he need for target vessel revascularization.
revious studies. Several observational studies have dem-
nstrated the efficacy of drug-eluting stents in patients with
SR. In a pioneer study Sousa el al. (11) demonstrated
xcellent long-term clinical and angiographic results with
he use of sirolimus stents in a relatively favorable patient
ohort. Subsequently, the value of these stents was demon-
trated in patients with more complex patterns of ISR,
ncluding those with occluded vessels and recurrences after
rachytherapy (12). Although the results of that study
ompared favorably with historical series, the recurrent
estenosis rate at 6 months was 20% (12). More recently
eumann et al. (13) reported the largest series (162 pa-
ients) treated with sirolimus stents for ISR. In that pro-
pective registry the binary restenosis rate was 9.7% and the
equirement for a new intervention in the target vessel 7.4%.
n the other hand, the use of paclitaxel-eluting stents in
atients with ISR has also generated considerable interest.
ts
oup BA Group p Value
6) (n  74)
0.5 2.68  0.4 0.80
0.3 0.70  0.3 0.54
13 74  11 0.32
9 15.7  9 0.40
49 (66) 0.05
6) (n  74)
0.4 2.80  0.4 0.12
0.4 2.29  0.4 0.001
6 18  9 0.001
0.5 1.59  0.4 0.001
0) (n  71)
.11) 2.70 (2.40–2.96) 0.03
.81) 1.54 (0.91–2.05) 0.001
40 (25–65) 0.001
28 (39) 0.001
–0.43) 0.69 (0.15–1.28) 0.001
–0.21) 0.43 (0.11–0.83) 0.001
.09) 0.89 (0.24–1.25) 0.001
0) (n  71)
.10) 2.70 (2.40–2.96) 0.08
.81) 1.54 (0.91–2.05) 0.001
40 (25–65) 0.001
28 (39) 0.001
–0.27) 0.69 (0.15–1.28) 0.001
–0.15) 0.43 (0.11–0.83) 0.001
.10) 0.89 (0.24–1.25) 0.001
ution (mean  SD). †Angiographic data at follow-up, not
with the median test.esul
S Gr
 7
6 
4 
2 
.9 
0)
 7
1 
9 
7 
5 
 7
.61–3
.09–2
–21)
1)
0.13
0.07
.39–2
 7
.60–3
.28–2
–17)
)
0.13
0.07
.47–2
distribn the In-Stent Restenosis Treated With Stent-Based
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er Formulation (TAXUS III) registry (14), including 28
atients, the mean late loss at 6 months was 0.54 mm and
he rate of adverse clinical events at 1 year was 29%.
Recently the results of the Intracoronary Stenting with
ntithrombotic Regimen-Drug-Eluting Stents for In-Stent
estenosis (ISAR-DESIRE) randomized study have been
eported (21). This study allocated 300 patients with ISR to
alloon therapy, sirolimus stent, or paclitaxel stent implan-
ation. Both drug-eluting stents proved to be superior to
igure 3. Restenosis risk according to treatment allocation and ten presp
ecurrence was found in the sirolimus-eluting stent (SES) group. No pati
alloon angioplasty; B/A  balloon/artery ratio; CI  confidence intervalalloon angioplasty. In a secondary analysis, however, the cirolimus stent had a trend to a lower rate of angiographic
estenosis (14.3% vs. 21.7%) and significantly reduced late
umen loss (median 0.32 vs. 0.55 mm) and the rate of target
essel revascularization (8% vs. 19%) compared with the
aclitaxel stent. Intravascular ultrasound studies, however,
ere not performed in this trial.
Multiple randomized trials have unequivocally demon-
trated the superiority of brachytherapy over balloon angio-
lasty in this adverse anatomic setting. Brachytherapy,
owever, is limited by inherent logistics, cumbersome pro-
variables. The relative risk for short lesions was undefined, because 0%
ith in-stent restenosis of a coil stent (first ST Coil) was included. BA 
 left anterior descending coronary artery; RE  restenosis.ecified
ent wedures, concern of edge effects, a prolonged risk of vessel
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Sirolimus Stents for In-Stent Restenosis June 6, 2006:2152–60cclusion and a decrease in benefit over time (22). In Spain,
nly 3% of all PCI performed for ISR in 2003 used
rachytherapy (3), and since 2005 this therapy is no longer
vailable. In this regard, recent studies in patients with ISR
atched for clinical and angiographic variables (15–17)
uggest the superiority of drug-eluting stents (both pacli-
axel and sirolimus) over brachytherapy.
urrent study. Some findings of the present study deserve
urther comments. The median late loss of 0.13 found in our
tudy favorably compares with the 0.32 mm late loss found
n the ISAR-DESIRE trial (21). In addition, in our study,
n-stent and in-segment late loss were nearly identical
excluding the presence of significant edge effects), whereas
n ISAR-DESIRE in-segment late loss was three times the
n-stent late loss. Nevertheless, 11% of our patients devel-
ped recurrences. The reason for treatment failure in these
atients remains unclear. We were unable to identify pre-
ictors of this complication other than sirolimus stent
ength. Similar findings have been reported by other inves-
igators (13). However, Fujii et al. (23) suggested that severe
tent underexpansion could represent a marker of patients
ith a higher risk for recurrences. In this regard the high
mplantation pressures used in our study were designed in
n attempt to prevent this problem. Vessel size is yet
nother potentially important factor to explain recurrences.
n the present study as well as in previous studies (13,21)
atients treated for ISR had relatively small vessels which
ould facilitate the appearance of recurrences for any given
ngiographic late loss. Finally, 35% of patients in the
urrent study were diabetic (38% in the sirolimus stent
roup). This number is higher than that found in other
revious ISR trials (7,8,21), including the RIBS-I study
26% diabetic) (10).
The pattern of late angiographic findings was also of
nterest. Notably, at follow-up we found a skewed distribu-
ion of most late angiographic variables, mainly affecting the
irolimus stent group. The implications of this finding have
een recently emphasized in some drug-eluting stent trials
24,25). It is important to keep in mind that at late
ollow-up most patients maintain excellent angiographic
nd ultrasound results, with findings difficult to differentiate
rom those seen immediately after the procedure. However,
small but sizable number of patients behave differently,
xperiencing significant neointimal proliferation and even-
ually developing severe recurrent ISR. This distinct bi-
odal distribution pattern explains late angiographic data
ot being normally distributed. Furthermore, as previously
escribed (23) patients with recurrences after sirolimus
tenting tend to present with a relatively “focal” pattern of
SR which, at least on theoretical grounds, could facilitate a
enign outcome after subsequent treatment.
Finally, our IVUS substudy complements previous find-
ngs and confirms the value of sirolimus stents to markedly
nhibit recurrent neointimal proliferation in patients with
SR. As a result, lumen volume at follow-up (both in-igure 4. Box whisker plot (median and interquartile range) of intravas-
ular ultrasound findings at follow-up. (A) In-segment lumen volume. (B)
n-stent lumen volume. (C) Neointimal proliferation volume. The median
est was used to compare results between the two arms. The paired sample
ign test was used to assess changes within each arm. p  0.05 (stent
roup, post-procedure vs. follow-up [FU]). BA  balloon angioplasty
blue); PRE  before the procedure; POST  after intervention; SES egment and in-stent analyses) was significantly larger in the
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June 6, 2006:2152–60 Sirolimus Stents for In-Stent Restenosisirolimus stent group. Of interest, in the sirolimus stent
roup lumen volume at follow-up increased in the in-
egment analysis and decreased in the in-lesion (stent)
nalysis. Furthermore, although initial results were signifi-
antly better in the sirolimus stent arm the main factor
ccounting for the larger coronary lumen at follow-up in
his arm was the striking inhibition of neointimal prolifer-
tion. This provides comprehensive mechanistic insights on
he efficacy of these stents in this challenging scenario.
tudy limitations. First, only patients with ISR after
are-metal stenting were included. Therefore, the efficacy of
he studied strategies in patients with ISR after drug-eluting
tenting would require additional investigation. Second,
atients with occluded stents and very diffuse ISR were not
ncluded. Third, the lack of a brachytherapy arm prevents
omparing the results of sirolimus-eluting stents with this well
stablished therapy for ISR. Lastly, IVUS studies were not
btained in all patients. However, results of our IVUS substudy
ere consistent with the main findings of the study.
ONCLUSIONS
his randomized controlled clinical trial demonstrates that
n patients with ISR the use of sirolimus-eluting stents
rovides superior long-term clinical, angiographic, and
VUS outcome compared with conventional balloon angio-
lasty and, therefore, should be recommended.
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Table 3. In-Hospital and One-Year Clinical E
Event
SES Group
(n  76)
Hospital events, n (%)
Death 1 (1.3)
Myocardial infarction 0 (0)
Target vessel revascularization 0 (0)
Coronary angioplasty 0 (0)
Coronary surgery 0 (0)
Any major hospital event 1 (1.3)
Events at 9 months, n (%)
Death 3 (3.9)
Myocardial infarction 2 (2.6)
Target vessel revascularization 3 (3.9)
Coronary angioplasty 2 (2.6)
Coronary surgery 1 (1.3)
Any major event at 9 months 4 (5.3)
Events at 1 year, n (%)
Death 3 (3.9)
Myocardial infarction 2 (2.6)
Target vessel revascularization 8 (10.5)
Coronary angioplasty 7 (9.2)
Coronary surgery 1 (1.3)
Any major event at 1 year 9 (11.8)
Patients with more than one event are counted only once fo
separately in the corresponding category. p values from Cox
CI  confidence intervals; HR  hazard ratio; —  uney, Madrid 28040, Spain. E-mail: falf@hotmail.com.EFERENCES
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